BR
Therapeutic Areas
Atea Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Bemnifosbuvir / Ruzasvir | Hepatitis C Virus (HCV) | Phase 3 |
| AT-587 | Hepatitis E Virus (HEV) | Preclinical |
| AT-527 | COVID-19 | Phase 2 |
Leadership Team at Atea Pharmaceuticals
JS
Jean-Pierre Sommadossi, PhD
Founder, Chairman & CEO
NA
Nancy Agrawal, PhD
Executive VP, Preclinical Development
JB
Jonae Barnes
Senior VP, Investor Relations & Corporate Communications
BB
Bruce Belanger, PhD
Senior VP, Biostatistics
AC
Andrea Corcoran
CFO & Executive VP, Legal
AD
Adam DeZure, MD
VP, Clinical Development
JM
James MB Evans, PhD
Senior VP, CMC Manufacturing
WF
Wayne Foster
Executive VP, Chief Accounting Officer
SG
Steven Good
Executive VP, Preclinical Science
JH
Janet Hammond, MD, PhD
Chief Development Officer